A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation

AUTHORS: Pengyi Li et al

BMC Pulm Med. 2022 Jan 13; 22(1): 37

BACKGROUND Prostaglandin E1 (PGE1) has been reported to maintain adequate oxygenation among patients under 60% FiO 2 one-lung ventilation (OLV). This research aimed to explore whether PGE1 is safe in pulmonary shunt and oxygenation under 40% FiO 2 OLV and provide a reference concentration of PGE1.

METHODS Totally 90 esophageal cancer patients treated with thoracotomy were enrolled in this study, randomly divided into three groups (n = 30/group): Group A (60% FiO 2 and 0.1 µg/kg PGE1), Group B (40% FiO 2 and 0.1 µg/kg PGE1), and Group C (40% FiO 2 , 0.2 µg/kg PGE1). Primary outcomes were oxygenation and pulmonary shunt during OLV. Secondary outcomes included oxidative stress after OLV.

RESULTS During OLV, patients in Group C and B had lower levels of PaO 2 , SaO 2 , SpO 2 , MAP, and Qs/Qt than those in Group A

Leave a Reply

Your email address will not be published. Required fields are marked *